The EasyM™ test is being developed by Rapid Novor, a Canadian biotech company founded in 2015. The proteomics mass spectrometry and bioinformatics technology we have developed have empowered thousands of researchers to develop diagnostics, therapies, reagents, and treatments. Our vision is to elevate human health by decoding immunity. Once certified, EasyM™ will be Rapid Novor’s first proprietary clinical application of our established protein sequencing technology. As Canada’s largest privately-owned mass spectrometry proteomics facility, we are capable of processing and analyzing clinical samples from patients with Multiple Myeloma. Our team of scientists is committed to championing better testing for Multiple Myeloma. Combined, the EasyM team at Rapid Novor has decades of experience in mass spectrometry, algorithm development, process development, clinical assay development, and clinical lab management.